MX343271B - Procesos de cultivo celular. - Google Patents

Procesos de cultivo celular.

Info

Publication number
MX343271B
MX343271B MX2014003366A MX2014003366A MX343271B MX 343271 B MX343271 B MX 343271B MX 2014003366 A MX2014003366 A MX 2014003366A MX 2014003366 A MX2014003366 A MX 2014003366A MX 343271 B MX343271 B MX 343271B
Authority
MX
Mexico
Prior art keywords
cell culture
culture processes
urin
adamts
cho
Prior art date
Application number
MX2014003366A
Other languages
English (en)
Spanish (es)
Inventor
Giovagnoli Andre
Roy Sylvain
Ducros Veronique
Charlot Virginie
Stauffer Yves-Olivier
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX343271B publication Critical patent/MX343271B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21075—Furin (3.4.21.75)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MX2014003366A 2007-12-27 2008-12-22 Procesos de cultivo celular. MX343271B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US932807P 2007-12-27 2007-12-27
PCT/US2008/088036 WO2009086309A2 (en) 2007-12-27 2008-12-22 Cell culture processes

Publications (1)

Publication Number Publication Date
MX343271B true MX343271B (es) 2016-10-31

Family

ID=40350258

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014003366A MX343271B (es) 2007-12-27 2008-12-22 Procesos de cultivo celular.
MX2015014311A MX343269B (es) 2007-12-27 2008-12-22 Procesos de cultivo celular.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015014311A MX343269B (es) 2007-12-27 2008-12-22 Procesos de cultivo celular.

Country Status (21)

Country Link
US (2) US9359629B2 (https=)
EP (4) EP2574677B1 (https=)
JP (3) JP5727790B2 (https=)
KR (4) KR101798813B1 (https=)
CN (2) CN101910408A (https=)
AR (2) AR069956A1 (https=)
AU (1) AU2008345231B2 (https=)
BR (1) BR122019022434B8 (https=)
CA (1) CA2709890A1 (https=)
DK (3) DK2574677T3 (https=)
ES (3) ES2647294T3 (https=)
HK (1) HK1246827A1 (https=)
HR (3) HRP20171375T1 (https=)
HU (2) HUE036712T2 (https=)
MX (2) MX343271B (https=)
NZ (1) NZ586250A (https=)
PL (3) PL2235197T3 (https=)
PT (3) PT2574676T (https=)
SG (2) SG187397A1 (https=)
SI (3) SI2574677T1 (https=)
WO (1) WO2009086309A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
SI4269578T1 (sl) 2008-03-06 2024-07-31 Halozyme, Inc. Sestava topne hialuronidaze
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
BRPI0920572A8 (pt) 2008-10-20 2015-10-27 Abbott Lab Inativação viral durante a purificação dos anticorpos
US8580554B2 (en) * 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
CN104962539B (zh) * 2009-07-31 2019-09-17 百深公司 用于adamts蛋白表达的细胞培养基
WO2012006594A1 (en) * 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant adamts13 in cell culture
BR112013023167A2 (pt) * 2011-03-11 2016-09-06 Univ São Paulo método para produção do fator viii humano recombinante, fator viii humano recombinante, produto farmacêutico, uso do fator viii humano recombinante, método para tratamento de doenças relacionadas à diminuição, inativação ou ausência de fator viii, uso da endoprotease spc6 e/ou da pace4 ai e/ou da pacesol e processamento proteolítico do fator viii humano recombinante
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
KR20150026024A (ko) * 2013-08-30 2015-03-11 한미약품 주식회사 인간 혈액응고 7인자 유도체의 대량 생산 방법
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
HRP20200372T1 (hr) 2014-03-25 2020-06-12 F. Hoffmann - La Roche Ag Postupci proizvodnje poloksamera za upotrebu u mediju za staničnu kulturu
US10227559B2 (en) * 2014-04-10 2019-03-12 Bayer Healthcare Llc Compounded media powder formulation and method of preparation of liquid medium for cell culture
MA40021A (fr) * 2014-06-03 2015-12-10 Lupin Ltd Processus de culture cellulaire destiné à produire une protéine
AU2015269365A1 (en) 2014-06-04 2016-12-15 Amgen Inc. Methods for harvesting mammalian cell cultures
JP6651548B2 (ja) 2015-05-22 2020-02-19 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォン・ヴィルブランド因子を製造するための方法
WO2018073365A1 (en) * 2016-10-19 2018-04-26 F. Hoffmann-La Roche Ag Method for producing an immunoconjugate
CN114657118B (zh) * 2021-12-31 2023-12-01 广州齐志生物工程设备有限公司 一种2bs细胞在生物反应器内的多倍放大方法
WO2024228717A2 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. Fentanyl-specific single variable-domain antibodies and use in a continuous agglutination assay
CN116064409A (zh) * 2023-01-06 2023-05-05 四川阿思科力生物科技有限公司 一种大规模高产量细胞连续培养和收获的生产工艺
WO2024226439A1 (en) 2023-04-24 2024-10-31 Quantitative Biosciences, Inc. Engineered biosensor strains of e. coli for continuous aerobic detection of analytes
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
EP4711442A1 (en) 2024-09-15 2026-03-18 Quantitative Biosciences, Inc. Microfluidic chip for the parallel culture of microbial biosensor strains

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4921792A (en) * 1987-11-27 1990-05-01 Miles Inc. Continuous cell dispersion, cultivation and substance recovery process
JPH0787799B2 (ja) * 1988-03-30 1995-09-27 森永製菓株式会社 モノクローナル抗体生産増強法
US6100050A (en) 1989-08-17 2000-08-08 Dade Behring Ag Factor VIII:Ca chromogenic assay
NL9000917A (nl) 1989-10-25 1991-05-16 Holland Biotechnology Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van (precursor) eiwitten en voor de (micro) biologische bereiding van eiwitten.
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
AT393356B (de) * 1989-12-22 1991-10-10 Immuno Ag Verfahren zur herstellung von fsme-virus-antigen
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
ATE158816T1 (de) 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
WO1992015686A1 (en) 1991-02-28 1992-09-17 Zymogenetics, Inc. Modified factor vii
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
AT403167B (de) 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
WO1997021824A2 (en) * 1995-12-15 1997-06-19 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
AT403765B (de) * 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
WO1998000521A1 (fr) * 1996-06-28 1998-01-08 The Green Cross Corporation Milieux exempts de serum, methode de culture de cellules d'origine animale, et procede de production de substances physiologiquement actives
US5854021A (en) 1997-02-28 1998-12-29 Bayer Corporation Enhance protein production method
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
DE60024268T2 (de) 1999-07-13 2006-08-03 Biovitrum Ab Zusammensetzungen mit stabilem faktor viii
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
SE518174C2 (sv) * 1999-11-16 2002-09-03 Appliedsensor Sweden Ab Detektionsförfarande av oönskad mikrobiell infektion i animaliecellodling
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US6168941B1 (en) * 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
JP4455802B2 (ja) 2000-05-03 2010-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト第ｖｉｉ凝固因子変異型
WO2002022776A2 (en) 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
US20040185535A1 (en) * 2003-03-21 2004-09-23 Giles Wilson Industrial-scale serum-free production of recombinant FVII in mammalian cells
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
CZ20032454A3 (en) 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
JP2003047461A (ja) * 2001-07-31 2003-02-18 Astec:Kk アパタイトシ−トを用いた細胞の高密度細胞培養法及び培養装置、細胞培養モジュール
DK1451290T3 (da) * 2001-08-31 2011-04-26 Bayer Schering Pharma Ag Indretning og fremgangsmåde til udførelse af fermentering af høj celledensitet
CZ2004427A3 (cs) 2001-09-27 2004-08-18 Novoánordiskáhealthácareáag Polypeptidy lidského koagulačního faktoru VII
EP1434857B1 (en) * 2001-10-02 2007-08-01 Novo Nordisk Health Care AG Method for production of recombinant proteins in eukaryote cells
JP2005512524A (ja) 2001-11-02 2005-05-12 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
US20030119723A1 (en) 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
EP2287288B1 (en) * 2002-07-09 2012-11-07 Baxter International Inc. Animal protein free media for cultivation of cells
JP4651536B2 (ja) * 2003-04-17 2011-03-16 田辺三菱製薬株式会社 組換えアンチトロンビンの製造方法
CA2557046A1 (en) * 2004-03-05 2005-10-13 John Crowley Process for cell culturing by continuous perfusion and alternating tangential flow
EP1851305B1 (en) * 2005-02-11 2012-01-18 Novo Nordisk Health Care AG Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
ES2474573T3 (es) * 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
WO2008141824A2 (en) 2007-05-22 2008-11-27 Baxter International Inc. Preparative purification process for human furin

Also Published As

Publication number Publication date
HRP20171495T1 (hr) 2018-01-26
HUE036712T2 (hu) 2018-07-30
PT2235197T (pt) 2017-10-11
JP2011507551A (ja) 2011-03-10
BR122019022434B1 (pt) 2020-11-03
ES2644089T3 (es) 2017-11-27
PL2574677T3 (pl) 2017-12-29
EP3255152A1 (en) 2017-12-13
PT2574677T (pt) 2017-10-19
HUE036496T2 (hu) 2018-07-30
AU2008345231B2 (en) 2014-09-11
HRP20171375T1 (hr) 2017-12-15
KR101798813B1 (ko) 2017-11-16
SI2574676T1 (sl) 2017-10-30
JP5727790B2 (ja) 2015-06-03
DK2574676T3 (en) 2017-10-09
SG187397A1 (en) 2013-02-28
NZ586250A (en) 2012-11-30
KR20180005287A (ko) 2018-01-15
SG10201503304RA (en) 2015-06-29
ES2647294T3 (es) 2017-12-20
KR101818411B1 (ko) 2018-01-12
KR20100097752A (ko) 2010-09-03
US20160244506A1 (en) 2016-08-25
SI2235197T1 (sl) 2017-10-30
DK2574677T3 (da) 2017-11-06
MX343269B (es) 2016-10-31
KR20160112025A (ko) 2016-09-27
EP2574676A1 (en) 2013-04-03
PT2574676T (pt) 2017-10-11
WO2009086309A3 (en) 2009-10-01
KR20170126514A (ko) 2017-11-17
US9359629B2 (en) 2016-06-07
US20090176269A1 (en) 2009-07-09
DK2235197T3 (en) 2017-10-09
WO2009086309A2 (en) 2009-07-09
HRP20171374T1 (hr) 2017-12-29
ES2649094T3 (es) 2018-01-10
JP2014100148A (ja) 2014-06-05
JP5890854B2 (ja) 2016-03-22
EP2235197A2 (en) 2010-10-06
CN106222220A (zh) 2016-12-14
EP2574676B1 (en) 2017-08-30
BR122019022434B8 (pt) 2021-07-27
BRPI0821481A2 (pt) 2014-11-04
HK1246827A1 (en) 2018-09-14
PL2574676T3 (pl) 2017-12-29
EP2235197B1 (en) 2017-07-26
SI2574677T1 (sl) 2017-11-30
AR069956A1 (es) 2010-03-03
EP2574677B1 (en) 2017-09-13
AR110864A2 (es) 2019-05-08
AU2008345231A1 (en) 2009-07-09
EP2574677A1 (en) 2013-04-03
KR101659458B1 (ko) 2016-09-23
CA2709890A1 (en) 2009-07-09
PL2235197T3 (pl) 2018-01-31
CN101910408A (zh) 2010-12-08
JP2016013140A (ja) 2016-01-28

Similar Documents

Publication Publication Date Title
MX343271B (es) Procesos de cultivo celular.
AU2019268194A1 (en) Cell culture system
GB2446525A (en) Stem cell culture medium and method
MX2009010154A (es) Materiales y metodos para la produccion eficiente de succinato y malato.
EP2275531A4 (en) METHOD FOR IMPROVING A PLURIPOTENTIAL STEM CELL
GB2452456A (en) Cell growth medium
CL2011001926A1 (es) Biorreactor para el cultivo de celulas de mamiferos donde dicho biorreactor posee un volumen de al menos 4000 l y al menos un impulsor superior y al menos un impulsor de fondo, donde el impulsor superior es un impulsor de hidroplano; metodo de cultivo; sistema de bioreactor.
TW200736399A (en) Expansion and differentiation of neural stem cells under low oxygen conditions
MX2009011805A (es) Mejora de las concentraciones de polipeptido del factor viii en cultivos celulares.
MX2007002380A (es) Produccion de polipeptidos.
CR20120560A (es) PRODUCCIÓN DE TNFR-Ig Y FUSIÓN DE PROTEÍNA
CL2008001156A1 (es) Metodo para producir una proteina de fusion tnfr en un cultivo celular que comprende cultivar celulas de mamifero que contienen un gen que codifica la proteina de fusion en un medio de cultivo de celulas que comprende un compuesto anti-envejecimiento.
WO2008135498A3 (en) Prevention of protein degradation in mammalian cell cultures
DE602005002829D1 (de) Verwendung eines serumfreien zellkulturmediums zur produktion von il-18bp in säugerzellen
NO20072719L (no) Serumfritt cellekulturmedium for pattedyrceller
GB0702261D0 (en) No title
ATE336567T1 (de) Zellkulturmedium
TW200636068A (en) A method of culturing a cell and use of the same
NZ599479A (en) Improved reverse genetics methods for virus rescue
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
PT2401383E (pt) Métodos para seleccionar células eucarióticas que expressam uma proteína heteróloga
MX2010005079A (es) Metodos para medir la viabilidad celular sin usar celulas de control.
WO2004078915A3 (en) Cell culture
MX2007005210A (es) Medio de cultivo de celula libre de suero para las celulas de los mamiferos.
WO2004087860A3 (en) Materials and methods for regulating process formation in cell culture